Results comparison of cervical cancer early detection using cerviray ® with VIA test

Abstract Objectives This study investigates the performance of artificial intelligence (AI) technology, namely Cerviray AI®, compared with Cerviray® expert, aiming to compare its sensitivity, specificity, positive predictive value (PPV), and area under the receiver operating characteristic curve (AU...

Full description

Saved in:
Bibliographic Details
Main Authors: Ali Budi Harsono, Hadi Susiarno, Dodi Suardi, Kemala Isnainiasih Mantilidewi, Viko Duvadilan Wibowo, Yudi Mulyana Hidayat
Format: Article
Language:English
Published: BMC 2025-01-01
Series:BMC Research Notes
Subjects:
Online Access:https://doi.org/10.1186/s13104-025-07086-6
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832586072810323968
author Ali Budi Harsono
Hadi Susiarno
Dodi Suardi
Kemala Isnainiasih Mantilidewi
Viko Duvadilan Wibowo
Yudi Mulyana Hidayat
author_facet Ali Budi Harsono
Hadi Susiarno
Dodi Suardi
Kemala Isnainiasih Mantilidewi
Viko Duvadilan Wibowo
Yudi Mulyana Hidayat
author_sort Ali Budi Harsono
collection DOAJ
description Abstract Objectives This study investigates the performance of artificial intelligence (AI) technology, namely Cerviray AI®, compared with Cerviray® expert, aiming to compare its sensitivity, specificity, positive predictive value (PPV), and area under the receiver operating characteristic curve (AUC ROC). The Visual Inspection with Acetic Acid (VIA) test is used as the gold standard. Results The study involved 44 patients from various health centers in West Java Province. Performance of Cerviray AI®, or Cerviray® expert, and lastly VIA tests were compared in their ability to detect pre-cancerous cervical lesions in high-risk women of childbearing age. The current study indicated that Cerviray AI® had a sensitivity of 42.9%, specificity of 100%, PPV of 100%, and ROC AUC values of 71.4%. In comparison, the evaluation of the Cerviray® expert demonstrated a sensitivity of 71.4%, specificity of 97.3%, PPV of 83.3%, and ROC AUC values of 84.4%. In conclusion, the evaluation of Cerviray® expert outperformed Cerviray AI® in ROC AUC values. Trial registration Clinical Trials.gov Identifier NCT06518070 Retrospectively registered.
format Article
id doaj-art-892a42e034e3453bb883c25c2c1c26a7
institution Kabale University
issn 1756-0500
language English
publishDate 2025-01-01
publisher BMC
record_format Article
series BMC Research Notes
spelling doaj-art-892a42e034e3453bb883c25c2c1c26a72025-01-26T12:13:23ZengBMCBMC Research Notes1756-05002025-01-011811610.1186/s13104-025-07086-6Results comparison of cervical cancer early detection using cerviray ® with VIA testAli Budi Harsono0Hadi Susiarno1Dodi Suardi2Kemala Isnainiasih Mantilidewi3Viko Duvadilan Wibowo4Yudi Mulyana Hidayat5Department of Obstetrics and Gynecology, Faculty of Medicine, Universitas Padjadjaran–Dr. Hasan Sadikin General HospitalDepartment of Obstetrics and Gynecology, Faculty of Medicine, Universitas Padjadjaran–Dr. Hasan Sadikin General HospitalDepartment of Obstetrics and Gynecology, Faculty of Medicine, Universitas Padjadjaran–Dr. Hasan Sadikin General HospitalDepartment of Obstetrics and Gynecology, Faculty of Medicine, Universitas Padjadjaran–Dr. Hasan Sadikin General HospitalDepartment of Obstetrics and Gynecology, Faculty of Medicine, Universitas Padjadjaran–Dr. Hasan Sadikin General HospitalDepartment of Obstetrics and Gynecology, Faculty of Medicine, Universitas Padjadjaran–Dr. Hasan Sadikin General HospitalAbstract Objectives This study investigates the performance of artificial intelligence (AI) technology, namely Cerviray AI®, compared with Cerviray® expert, aiming to compare its sensitivity, specificity, positive predictive value (PPV), and area under the receiver operating characteristic curve (AUC ROC). The Visual Inspection with Acetic Acid (VIA) test is used as the gold standard. Results The study involved 44 patients from various health centers in West Java Province. Performance of Cerviray AI®, or Cerviray® expert, and lastly VIA tests were compared in their ability to detect pre-cancerous cervical lesions in high-risk women of childbearing age. The current study indicated that Cerviray AI® had a sensitivity of 42.9%, specificity of 100%, PPV of 100%, and ROC AUC values of 71.4%. In comparison, the evaluation of the Cerviray® expert demonstrated a sensitivity of 71.4%, specificity of 97.3%, PPV of 83.3%, and ROC AUC values of 84.4%. In conclusion, the evaluation of Cerviray® expert outperformed Cerviray AI® in ROC AUC values. Trial registration Clinical Trials.gov Identifier NCT06518070 Retrospectively registered.https://doi.org/10.1186/s13104-025-07086-6Cervical cancerCervirayVIA testEarly detection
spellingShingle Ali Budi Harsono
Hadi Susiarno
Dodi Suardi
Kemala Isnainiasih Mantilidewi
Viko Duvadilan Wibowo
Yudi Mulyana Hidayat
Results comparison of cervical cancer early detection using cerviray ® with VIA test
BMC Research Notes
Cervical cancer
Cerviray
VIA test
Early detection
title Results comparison of cervical cancer early detection using cerviray ® with VIA test
title_full Results comparison of cervical cancer early detection using cerviray ® with VIA test
title_fullStr Results comparison of cervical cancer early detection using cerviray ® with VIA test
title_full_unstemmed Results comparison of cervical cancer early detection using cerviray ® with VIA test
title_short Results comparison of cervical cancer early detection using cerviray ® with VIA test
title_sort results comparison of cervical cancer early detection using cerviray r with via test
topic Cervical cancer
Cerviray
VIA test
Early detection
url https://doi.org/10.1186/s13104-025-07086-6
work_keys_str_mv AT alibudiharsono resultscomparisonofcervicalcancerearlydetectionusingcerviraywithviatest
AT hadisusiarno resultscomparisonofcervicalcancerearlydetectionusingcerviraywithviatest
AT dodisuardi resultscomparisonofcervicalcancerearlydetectionusingcerviraywithviatest
AT kemalaisnainiasihmantilidewi resultscomparisonofcervicalcancerearlydetectionusingcerviraywithviatest
AT vikoduvadilanwibowo resultscomparisonofcervicalcancerearlydetectionusingcerviraywithviatest
AT yudimulyanahidayat resultscomparisonofcervicalcancerearlydetectionusingcerviraywithviatest